MediWound (MDWD) said Thursday it will start a phase II clinical study in 2025 evaluating EscharEx versus a collagenase ointment that's marketed as Santyl in the US and Iruxol in Europe to treat venous leg ulcers.
The study will enroll 45 patients in the US and Europe and will run concurrently with the company's phase III trial in venous leg ulcer patients.
MediWound said the study is designed to support the biologics license application for EscharEx.
The company's shares were up nearly 1% in recent trading.
Price: 16.65, Change: +0.15, Percent Change: +0.91
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。